Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs)
- PMID: 2688082
- DOI: 10.3109/03009748909103719
Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs)
Abstract
Investigations have shown that elderly patients have an increased sensitivity to the effects of non-steroidal anti-inflammatory drugs (NSAIDs) with a concomitant higher frequency of side-effects. Several explanations for such an observation are possible including altered receptor responsiveness or changes in absorption and disposition of a drug. From a literature survey it becomes clear that the rate and extent of NSAID absorption do not appear to be changed to a clinically significant degree in the elderly patient. Most NSAIDs are eliminated predominantly by hepatic metabolism and metabolic clearance therefore controls their elimination and accumulation upon chronic dosage. Differences in the dependence of these disposition processes on age exist between the commonly used NSAIDs. In our studies with tenoxicam, steady-state concentrations and accumulation factors did not differ in elderly subjects from those observed in a young population. Therefore, no dosage adjustment of this drug is necessary in elderly patients to achieve similar plasma concentrations following standard dosing in young subjects. Disposition processes of propionic acid derivatives seem to be more affected by advanced age as shown by reports in the literature. Alterations in plasma protein binding, with an increased free fraction of the drug subsequent to changes in serum albumin concentrations were reported with naproxen and salicylates in the aged population. Similarly, ketoprofen and ibuprofen clearance were significantly lower in the elderly than in young volunteers, and an accumulation of naproxen was reported in the elderly after multiple dosing.
Similar articles
-
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.Clin Pharmacokinet. 1994 Feb;26(2):107-20. doi: 10.2165/00003088-199426020-00004. Clin Pharmacokinet. 1994. PMID: 8162655 Review.
-
Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.Clin Pharmacokinet. 1990 Jul;19(1):44-66. doi: 10.2165/00003088-199019010-00004. Clin Pharmacokinet. 1990. PMID: 2199127 Review.
-
Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.J Clin Pharmacol. 1997 Apr;37(4):267-78. doi: 10.1002/j.1552-4604.1997.tb04302.x. J Clin Pharmacol. 1997. PMID: 9115051 Clinical Trial.
-
Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.Pharmacol Toxicol. 2001 Nov;89(5):265-72. doi: 10.1034/j.1600-0773.2001.d01-158.x. Pharmacol Toxicol. 2001. PMID: 11881981 Clinical Trial.
-
Single and multiple dose pharmacokinetics of tenoxicam in the elderly.Eur J Clin Pharmacol. 1988;35(5):563-6. doi: 10.1007/BF00558254. Eur J Clin Pharmacol. 1988. PMID: 3266152
Cited by
-
Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.Drugs. 1991 Apr;41(4):625-46. doi: 10.2165/00003495-199141040-00008. Drugs. 1991. PMID: 1711963 Review.
-
Clinical pharmacokinetics of tenoxicam.Clin Pharmacokinet. 1994 Jan;26(1):16-43. doi: 10.2165/00003088-199426010-00003. Clin Pharmacokinet. 1994. PMID: 8137596 Review.
-
The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis.Br J Clin Pharmacol. 1995;39 Suppl 1(Suppl 1):3S-9S. doi: 10.1111/j.1365-2125.1995.tb04494.x. Br J Clin Pharmacol. 1995. PMID: 7547091 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources